Form 6-K GLAXOSMITHKLINE PLC For: Dec 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Leerink Positive on ViiV's (GSK) Acquisition of HIV Assets from Bristol-Myers Squibb (BMY)
December 18, 2015 2:27 PM ESTLeerink affirms GlaxoSmithKline (NYSE: GSK) with a Market Perform rating and 48 price target following news that ViiV Healthcare would acquire certain HIV assets from Bristol-Myers Squibb (NYSE: BMY).
Analyst Seamus Fernandez summarized: With an eye on GILD's... More
GlaxoSmithKline's (GSK) ViiV Healthcare to Acquire Certain HIV Assets from Bristol-Myers Squibb (BMY)
December 18, 2015 7:07 AM ESTGlaxoSmithKline (NYSE: GSK) announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb (NYSE: BMY), to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibb's portfolio of preclinical and discovery stage HIV research assets.
Under the terms agreed in the two transactions, ViiV Healthcare will acquire:
